The Virtual Press Room is a courtesy for corporate and institutional public relations professionals. Publication of material on this page does not constitute an endorsement by ASCO of any product or claim. For information about how to submit a press release to the Virtual Press Room, visit the For PR Professionals page.

2022 ASCO Annual Meeting 

American Oncology Network 
American Oncology Network Physicians Research Presented at ASCO22 (Abstract #e13636, 2500, 2506)

Amplified Sciences
Amplified Sciences to Present Abstract at the Annual Meeting of the American Society of Clinical Oncology (ASCO) (Abstract #4151)

AnHeart Therapeutics 
AnHeart Therapeutics and Innovent Biologics Present Updated Phase 2 Efficacy and Safety Data of Taletrectinib (ROS1 Inhibitor) at ASCO 2022 (Abstract #8572)

Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) 
Three-year follow up results from the TheraP study for people with metastatic prostate cancer shows continued benefits (Abstract #5000)
The updated results from the ENZAMET clinical trial show a clinically meaningful survival benefit from novel hormone therapy for people with metastatic hormone sensitive prostate cancer (LBA #5004)

Beigene
BeiGene Clinical Data Presentations at 2022 ASCO Annual Meeting Demonstrate Mature and Growing Oncology Portfolio (Abstracts 7521 and 7510)

Cancer Antibodies Inc.
Cancer Antibodies Inc. Announces Breakthrough Method of Finding Unique Targets on Cancer Cells (Abstract #2530)

Canopy
Canopy Presents Research on Patient Impact of ePRO-Based Patient Monitoring at 2022 American Society of Clinical Oncology Annual Meeting (Abstract #1508)

Caris Life Sciences
Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers Reflecting Its Commitment to Improving Outcomes for Patients at ASCO 2022 

Cellworks
Cellworks Singulaä TRI Provides Personalized OS and PFS Predictions for 18 NCCN Guideline GBM Therapies (Abstract #2053)
Cellworks Singulaä TRI Predicts Personalized Treatment Outcomes for Esophageal Adenocarcinoma Patients Beyond Standard Clinical Factors (Abstract #4064)

CG Oncology
CG Oncology Presents New Clinical Data on Two Ongoing Programs at The American Society of Clinical Oncology (ASCO) 2022 Annual Meeting (Abstract #4597 and 4574)

Elicio Therapeutics
Elicio Therapeutics Presents Design of Ongoing AMPLIFY-201 Study in mutant KRASDriven Cancers at ASCO Annual Meeting 2022 (Abstract #TPS2701)

Exelixis
Exelixis Announces Results from Phase 2 Trial of Cabozantinib in Combination with Pembrolizumab in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma at ASCO 2022 (Abstract #6008)
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022 (Abstract #4504 and 9005)

Florida Cancer Specialist & Research Institute
Florida Cancer Specialists & Research Institute Presents Clinical Research Results at 2022 ASCO® Annual Meeting 

Fox Chase Cancer Center
Fox Chase Researchers Explore Ancestry-Specific Genetic Risk for Triple-Negative Breast Cancer (Abstract #10517)
Fox Chase Researchers Examine Racial Differences in Treatment and Outcomes of First-Line Therapies For Kidney Cancer

Intensity Therapeutics
Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Ipilimumab in Patients with Relapsed, Refractory, Metastatic Sarcomas (Abstract #11515)
Intensity Therapeutics, The Ottawa Hospital and The Ontario Institute for Cancer Research Report INT230-6 Demonstrates Tumor Necrosis and Immune Activation in Early Stage Breast Cancers (Abstract #605; Poster: 376)
Intensity Therapeutics’ INT230-6 Demonstrates Increased Survival as Either Monotherapy or in Combination with Pembrolizumab in Patients with Relapsed, Refractory, Metastatic Solid Tumor Cancers (Abstract #2520; Poster: 17)

Ipsen
New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer (Abstract #9005, 4501, 4504, 6081, and 6083)

Kaiser Permanente
Kaiser Permanente studies at ASCO Annual Meeting highlight advances in cancer care delivery (Abstract #571, 1205, 12025, 12055, 12089, 265, 3552, and 6578)

Parker Institute for Cancer Immunotherapy (PICI)
Biomarkers May Predict Better Immunotherapy Treatment Outcomes for Certain Patients with Pancreatic Cancer (Abstract #4010)

Penn Medicine
Penn Medicine at the 2022 American Society of Clinical Oncology Annual Meeting and Exposition (Abstracts #109, 1501, 1593, 2548, 2533, 4010, 4021, 4131, 6057, 6510, 6527, 9022, S406 and TPS1603)
Initial Surgery May Be Associated with Lower Stroke Risk for Head and Neck Cancer Patients (Abstract #6057)
Promising Results for Chemo-Immunotherapy Combination Against Pancreatic Cancer, Penn Study Finds (Abstract #4010)

Perthera 
AT ASCO ’22, PERTHERA ANNOUNCES THE IMMEDIATE AVAILABILITY OF THE PERTHERA AI ANALYTICS PLATFORM TO CANCER CENTERS FOR IMPROVED ANALYTICS, CRITICAL TRIAL OPTIMIZATION AND PATIENT CARE MANAGEMENT (Poster #4124)

Prelude Corporation
PreludeDxTM to Present DCIS Study Results Assessing Benefit of Adjuvant Endocrine Therapy Using DCISionRTÒ During Oral Presentation at ASCO 2022 Annual Meeting (Abstract #502)
PreludeDx Presented New DCISionRT Data on the Effectiveness of Endocrine Therapy in DCIS Patients at the ASCO 2022 Annual Meeting (Abstract #502) 

Realm IDx
REALM IDx Collaborates on Three Studies Presented at ASCO 2022 (Abstract # 10502, 10514, and 5002)

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Present Expansive, Diverse and Compelling New Cancer Research at the 2022 ASCO Annual Meeting (Abstract #7503, 2506, 10001, TPS5602, 11026, 5548, 7519, 5514, 11013, 11551, 10043, TPS8597, and 5025)

Sierra Oncology
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting (Abstract #7002 and 7061)

SOPHiA GENETICS
SOPHiA GENETICS Provides an Update on its DEEP-Lung-IV Multimodal Clinical Study at ASCO 2022

Sunstone Therapies
First ever psychedelic research presented at ASCO shows positive mental health benefits of psilocybin-assisted therapy for cancer patients (Abstract #12097)

SWOG Cancer Research Network
Standing Physician Orders Did Not Improve Guideline Adherence in Prescriptions to Prevent Febrile Neutropenia (Abstract #1525 and 1518)
Cell-Free DNA Methylation Used to Predict Chemo Benefit in Bladder Cancer (Abstract #4506)
Desmoplastic Melanoma Responds to PD-1 Blockade Immunotherapy (Abstract #9502)
Percentage of SWOG Trial Participants on Medicaid Grew Significantly with ACA (Abstract #6505)
New Drug Combination Lengthened Survival for Some with Lung Cancer (Abstract #9004)
Everolimus after Surgery Can Improve Outcomes in Those with High-Risk Kidney Cancer (Abstract #LBA4500)

The University of Texas MD Anderson Cancer Center
Ibrutinib with chemoimmunotherapy improved progression-free survival for newly diagnosed mantle cell lymphoma patients (Abstract # LBA7502)
Studies reveal new insights into gut microbiome impact on immunotherapy response in multiple cancers, including glioblastoma (Abstract #2006 and 2011)
MD Anderson researchers present cellular therapy advances at the 2022 ASCO Annual Meeting (Abstract #7518, 7509, and 8009)
Immunotherapy before surgery associated with improved survival for soft-tissue sarcoma (LBA #11501)